Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-α control of the acute-phase response

Endocrinology

Volumn 149, Issue 6, 2008, Pages 3215-3223

  Mansouri, Roxane M ^a,b   Baugé, Eric ^a   Staels, Bart ^a,b   Gervois, Philippe ^a,b  

^a INSERM   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ACUTE-PHASE PROTEINS; ANIMALS; ATHEROSCLEROSIS; CELL NUCLEUS; GENE EXPRESSION REGULATION; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-8; LIVER; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; PPAR ALPHA; PROCETOFEN; RNA;

EID: 44249124486     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-1339     Document Type: Article

References (46)

1. Tedgui A, Mallat Z 2006 Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86:515-581
2. Ross R 1999 Atherosclerosis is an inflammatory disease. Am Heart J 138:S419-S420
3. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V 2000 Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209-214
4. Hoffmeister A, Rothenbacher D, Bazner U, Frohlich M, Brenner H, Hombach V, Koenig W 2001 Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 87:262-266
5. Dhainaut JF, Marin N, Mignon A, Vinsonneau C 2001 Hepatic response to sepsis: interaction between coagulation and inflammatory processes. Crit Care Med 29:S42-S47
6. Baumann H, Gauldie J 1994 The acute phase response. Immunol Today 15:74-80
7. Hirano T 1998 Interleukin 6 and its receptor: ten years later. Int Rev Immunol 16:249-284
8. Issemann I, Green S 1990 Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650
9. Issemann I, Prince RA, Tugwood JD, Green S 1993 The retinoid X receptor enhances the function of the peroxisome proliferator activated receptor. Biochimie (Paris) 75:251-256
10. Shulman AI, Mangelsdorf DJ 2005 Retinoid X receptor heterodimers in the metabolic syndrome. N Engl J Med 353:604-615
11. IJpenberg A, Jeannin E, Wahli W, Desvergne B 1997 Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem 272:20108-20117
12. Gervois P, Chopin-Delannoy S, Fadel A, Dubois G, Kosykh V, Fruchart JC, Najib J, Laudet V, Staels B 1999 Fibrates increase human REV-ERBα expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol Endocrinol 13:400-409
13. Gervois P, Fruchart JC, Staels B 2007 Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 3:145-156
14. Gervois P, Torra IP, Fruchart JC, Staels B 2000 Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 38:3-11
15. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B 1999 Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85:394-402
16. Gervois P, Vu-Dac N, Kleemann R, Kockx M, Dubois G, Laine B, Kosykh V, Fruchart JC, Kooistra T, Staels B 2001 Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β. J Biol Chem 276:33471-33477
17. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W 1996 The PPARα-leukotriene B4 pathway to inflammation control. Nature 384:39-43
18. Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T 2004 Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-α activator fenofibrate. J Biol Chem 279:16154-16160
19. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T 2003 Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation. Blood 101:545-551
20. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A 1998 Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPAR activators. Nature 393:790-793
21. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J 1999 PPARγ activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125-3131
22. Vanden Berghe W, Vermeulen L, Delerive P, De Bosscher K, Staels B, Haegeman G 2003 A paradigm for gene regulation: inflammation, NF-κB and PPAR. Adv Exp Med Biol 544:181-196
23. Gorski K, Carneiro M, Schibler U 1986 Tissue-specific in vitro transcription from the mouse albumin promoter. Cell 47:767-776
24. Nevins JR 1987 Isolation and analysis of nuclear RNA. Methods Enzymol 152:234-241
25. Berry MN, Friend DS 1969 High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol 43:506-520
26. Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W, Haegeman G 1998 p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-κB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 273:3285-3290
27. Hagstrom JE 2003 Plasmid-based gene delivery to target tissues in vivo: the intravascular approach. Curr Opin Mol Ther 5:338-344
28. Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, Gasiorowski JZ, Dean DA, Liu D 2004 Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 11:675-682
29. Al-Dosari MS, Knapp JE, Liu D 2005 Hydrodynamic delivery. Adv Genet 54:65-82
30. Andre FM, Cournil-Henrionnet C, Vernerey D, Opolon P, Mir LM 2006 Variability of naked DNA expression after direct local injection: the influence of the injection speed. Gene Ther 13:1619-1627
31. Zhang X, Dong X, Sawyer GJ, Collins L, Fabre JW 2004 Regional hydrodynamic gene delivery to the rat liver with physiological volumes of DNA solution. J Gene Med 6:693-703
32. Liu F, Song Y, Liu D 1999 Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6:1258-1266
33. Munoz C, Pascual-Salcedo D, Castellanos MC, Alfranca A, Aragones J, Vara A, Redondo JM, de Landazuri MO 1996 Pyrrolidine dithiocarbamate inhibits the production of interleukin-6, interleukin-8, and granulocyte-macrophage colony-stimulating factor by human endothelial cells in response to inflammatory mediators: modulation of NF-κB and AP-1 transcription factors activity. Blood 88:3482-3490
34. Akira S, Taga T, Kishimoto T 1993 Interleukin-6 in biology and medicine. Adv Immunol 54:1-78
35. Galkina E, Ley K 2007 Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 27:2292-2301
36. Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B 2006 Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-α activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 26:977-986
37. DeForge LE, Kenney JS, Jones ML, Warren JS, Remick DG 1992 Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation of LPS- and cytokine-stimulated components using antitumor necrosis factor and anti-IL-1 antibodies. J Immunol 148:2133-2141
38. Wanidworanun C, Strober W 1993 Predominant role of tumor necrosis factor-α in human monocyte IL-10 synthesis. J Immunol 151:6853-6861
39. Fang C, Yoon S, Tindberg N, Jarvelainen HA, Lindros KO, Ingelman-Sundberg M 2004 Hepatic expression of multiple acute phase proteins and downregulation of nuclear receptors after acute endotoxin exposure. Biochem Pharmacol 67:1389-1397
40. Feingold K, Kim MS, Shigenaga J, Moser A, Grunfeld C 2004 Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab 286:E201-E207
41. Stienstra R, Mandard S, Tan NS, Wahli W, Trautwein C, Richardson TA, Lichtenauer-Kaligis E, Kersten S, Muller M 2007 The interleukin-1 receptor antagonist is a direct target gene of PPARα in liver. J Hepatol 46:869-877
42. Libby P 2002 Inflammation in atherosclerosis. Nature 420:868-874
43. Zibara K, Chignier E, Covacho C, Poston R, Canard G, Hardy P, McGregor J 2000 Modulation of expression of endothelial intercellular adhesion molecule-1, platelet-endothelial cell adhesion molecule-1, and vascular cell adhesion molecule-1 in aortic arch lesions of apolipoprotein E-deficient compared with wild-type mice. Arterioscler Thromb Vasc Biol 20:2288-2296
44. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R 1998 Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 18:842-851
45. Dansky HM, Barlow CB, Lominska C, Sikes JL, Kao C, Weinsaft J, Cybulsky MI, Smith JD 2001 Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage. Arterioscler Thromb Vasc Biol 21:1662-1667
46. Nageh MF, Sandberg ET, Marotti KR, Lin AH, Melchior EP, Bullard DC, Beaudet AL 1997 Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol 17:1517-1520